LWB1
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more
Market Cap & Net Worth: LWB1 (LWB1)
LWB1 (F:LWB1) has a market capitalization of $1.66 Billion (€1.62 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #5047 globally and #525 in its home market, demonstrating a -10.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LWB1's stock price €12.60 by its total outstanding shares 128696980 (128.70 Million).
LWB1 Market Cap History: 2026 to 2026
LWB1's market capitalization history from 2026 to 2026. Data shows growth from $1.66 Billion to $1.66 Billion (0.00% CAGR).
LWB1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LWB1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LWB1 by Market Capitalization
Companies near LWB1 in the global market cap rankings as of March 18, 2026.
Key companies related to LWB1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
LWB1 Historical Marketcap From 2026 to 2026
Between 2026 and today, LWB1's market cap moved from $1.66 Billion to $ 1.66 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of LWB1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.66 Billion USD |
| MoneyControl | $1.66 Billion USD |
| MarketWatch | $1.66 Billion USD |
| marketcap.company | $1.66 Billion USD |
| Reuters | $1.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.